- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05701527
A Study of EBC-129 in Advanced Solid Tumours
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, open label study which is divided into 3 parts.
Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy.
Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab.
Part C (dose expansion cohort) will be performed in an expanded cohort of patients with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Venkateshan Srirangam Prativadibhayankara, MD
- Phone Number: +65 6407 4213
- Email: Venkateshan_Srirangam@eddc.sg
Study Contact Backup
- Name: Veronica Diermayr
- Phone Number: +65 6407 0706
- Email: Veronica_Diermayr@eddc.sg
Study Locations
-
-
South West
-
Singapore, South West, Singapore, 168583
- Recruiting
- National Cancer Centre Singapore
-
Principal Investigator:
- Ng Matthew
-
Singapore, South West, Singapore, 119228
- Recruiting
- National University Hospital - Medical Oncology
-
Principal Investigator:
- Yong Wei Peng
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045-2517
- Recruiting
- University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
-
Principal Investigator:
- Lentz Robert
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- UT MD Anderson Cancer Center
-
Principal Investigator:
- Meric-Bernstam Funda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients ≥18 years (US) or ≥21 years (Singapore) old
- Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study
- Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
- Hepatic function and adequate renal function, as per protocol standard
- Adequate bone marrow function as per protocol standard
Exclusion Criteria:
- Unable or not willing to provide tumour tissue sample (from archival tissue or de-novo biopsy) unless if there is a significant risk for the patient to undergo biopsy
- Has received investigational or anti-cancer therapy within 4 weeks (28 days) prior to starting study drug
- Is receiving any concomitant anti-cancer therapy
- Known severe hypersensitivity to E coli-derived products or filgrastim or peg-filgrastim and have significant allergies to such biological products
- Has clinically active brain metastases
- Has received prior radiation therapy
- Has received prophylactic administration of haematopoietic colony stimulating factors within 4 weeks (28 days) prior to starting study drug
- Patients concurrently using any strong P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P3A (CYP3A) inhibitors within 14 days prior to the first dose of study drug or patients that use restricted or prohibited medications listed in the concomitant and other treatments section of the protocol
- Pregnancy or breast feeding
For patients receiving pembrolizumab:
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Patients who, according to the currently approved Keytruda (pembrolizumab) US package insert (USPI)/summary of product characteristics, had an immune-related adverse event (irAE) for which permanent discontinuation is mandated (any Grade 4 event and Grade 3 events of pneumonitis, hepatitis, and nephritis). Also, patients without formal contraindication due to previous irAE with any immune checkpoint inhibitor (approved or investigational) are not eligible if the AE has not resolved to grade 1 or better and/or still requires steroids (>10 mg of prednisone equivalent per day) for ongoing management.
- Patients with a history of pneumonitis/interstitial lung disease, patients who received live vaccines within 30 days of enrolment, and patients who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis are excluded from enrolment into pembrolizumab-containing cohorts
- Has had a major surgical procedure within 4 weeks (28 days) from starting the study drug
- Patients with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy
- Active infection including HIV, Hepatitis B or Hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A-Cohort 1
Patients will be administered Dose 1 of EBC-129 as a monotherapy.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part A-Cohort 2
Patients will be administered Dose 2 of EBC-129 as a monotherapy.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part A-Cohort 3
Patients will be administered Dose 3 of EBC-129 as a monotherapy.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part A-Cohort 4
Patients will be administered Dose 4 of EBC-129 as a monotherapy.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part A-Cohort 5
Patients will be administered Dose 5 of EBC-129 as a monotherapy.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part B
Patients will be administered three different dose levels of EBC-129 in combination with a fixed dose of pembrolizumab.
|
Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
Experimental: Part C
Patients will be administered the highest dose of EBC-129 as a monotherapy at the RP2D determined in Part A of the study.
|
EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A and Part B- Determination of Maximum tolerated dose (MTD)
Time Frame: Approximately 2 years
|
Approximately 2 years
|
|
Part A and Part B- Determination of the Recommended Phase 2 dose (RP2D)
Time Frame: Approximately 2 years
|
Approximately 2 years
|
|
Part A, Part B and Part C- Number of patients with serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)
Time Frame: From pre-screening (≥28 days from planned date of treatment i.e. Day 1) until end of study (EOS i.e., 30 days from last dose). Approximately 2 years
|
From pre-screening (≥28 days from planned date of treatment i.e. Day 1) until end of study (EOS i.e., 30 days from last dose). Approximately 2 years
|
|
Part C- Objective response rate (ORR)
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
|
Day 1 through 12 cycles (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A, Part B and Part C- Time to Progression (TTP)
Time Frame: Approximately 3.3 years
|
The time from the date of the first dose until objective tumour progression.
|
Approximately 3.3 years
|
Part A, Part B and Part C- Overall Survival (OS)
Time Frame: Approximately 3.3 years
|
The time from the date of the first dose until death due to any cause.
|
Approximately 3.3 years
|
Part A, Part B and Part C- Maximum plasma concentration at steady state (Cmax_ss)
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Trough concentration (Ctrough,ss)
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Area under the curve at steady state (AUC0-21d_ss)
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Accumulation ratios
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Number of patients with detectable Anti-drug antibodies (ADAs)
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Number of patients with neutralising antibodies
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Time to maximum plasma concentration (Tmax) of EBC-129
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A, Part B and Part C- Half-life (t1/2) of EBC-129
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part B- Cmax of Pemrolizumab
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part B- Ctrough of Pemrolizumab
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part B- AUC0-21d of Pemrolizumab
Time Frame: Cycle 1 and 2 (each cycle is 21 days)
|
Cycle 1 and 2 (each cycle is 21 days)
|
|
Part B- Tmax of Pemrolizumab
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part B- t1/2 of Pemrolizumab
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
Day 1 through 12 cycles (each cycle is 21 days)
|
|
Part A and Part B- ORR
Time Frame: Day 1 through 12 cycles (each cycle is 21 days)
|
The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.
|
Day 1 through 12 cycles (each cycle is 21 days)
|
Part A, Part B and Part C- Disease control rate (DCR)
Time Frame: Approximately 3.3 years
|
The percentage of patients who have a best overall response (BOR) of CR or PR in the first 12 weeks or who have demonstrated standard deviation (SD) for a minimum interval of 12 weeks following the start of treatment, will be determined based on RECIST.
|
Approximately 3.3 years
|
Part A, Part B and Part C- Duration of Response (DoR)
Time Frame: Approximately 3.3 years
|
The time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.
|
Approximately 3.3 years
|
Part A, Part B and Part C- Progression Free Survival (PFS)
Time Frame: Approximately 3.3 years
|
The time from the date of first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression.
|
Approximately 3.3 years
|
Part A, Part B and Part C- Maximum Plasma Concentration (Cmax) of EBC-129
Time Frame: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days)
|
Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days)
|
|
Part A, Part B and Part C- Trough Concentration (Ctrough) of EBC-129
Time Frame: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days)
|
Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days)
|
|
Part A, Part B and Part C- Area under the plasma drug concentration-time curve from time zero to Day 21 post-dose (AUC0-21d) of EBC-129
Time Frame: Cycle 1 and Cycle 2 (each cycle is 21 days)
|
Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Part A- Comparison of tumour responses
Time Frame: Approximately 1.8 years
|
The tumour responses (RECIST 1.1) will be compared between preselected patients and not pre-selected/not expressing the antigen when centrally assessed by immunohistochemistry (IHC).
|
Approximately 1.8 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Venkateshan Srirangam Prativadibhayankara, MD, EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EBC-129-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumours
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited Kingdom, United States
-
Cancer Research UKTerminatedAdvanced Solid TumoursUnited Kingdom
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedAdvanced Solid TumoursCanada
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumoursChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Solid Tumours
-
AstraZenecaActive, not recruiting
-
Exscientia AI LimitedBiotrialTerminatedAdvanced Solid TumoursFrance, Belgium
-
RemeGen Co., Ltd.Recruiting
Clinical Trials on Pembrolizumab
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States
-
The University of Hong KongMerck Sharp & Dohme LLCUnknown
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden